Pain Therapeutics

Following a series of well received conferences, SMi are delighted to announce their 7th annual event on Pain Therapeutics. In recent years the pain therapeutics market has been growing extensively with the overall value now reaching over $23 billion.

This conference will address key issues surrounding the market, such as the extensive regulatory concerns, abuse and addiction to prescription opioid medication and compare and contrast the use of human and animal pain models and how to best maximise their use.

Industry experts, from key companies including AstraZeneca, Wyeth, Abbott and Merck, will discuss drug classes such as the breakthrough of TRP-V1, CB2 and chemokines. Consideration will also be given to translational pharmacology in pain, how it affects the market and why it is vital to link research and development. Network with an international audience and leading speakers as they discuss the unmet needs and clinical advances in drugs used to combat pain.

A must attend event for those working in the highly competitive field of pain therapeutics!

Hear contributions from leading industry experts, including:

- Prof Chas Bountra, Vice President & Head of Biology, GlaxoSmithKline
- Dr Wilson Compton, Director, Division of Epidemiology, Services & Prevention Research, National Institute on Drug Abuse, National Institutes of Health (NIH)
- Dr Boris Chizh, Director, Exploratory Pain Medicine, GlaxoSmithKline
- Dr Kathryn Rogers, Director, Neuroscience Research, Wyeth Research
- Prof Irene Tracey, Director, FMRIB Centre & Pain Imaging Neuroscience Group, Oxford University
- Dr Catherine Abbadie, Research Fellow, Merck
- Dr Arthur Gomtsyan, Associate Research Fellow, Abbott
- Dr Uri Herzberg, Principal Scientist, Johnson & Johnson
- Dr Alf Claesson, Principal Scientist, AstraZeneca
- Dr Garth Whiteside, Principal Research Scientist I, Wyeth Research